Introduction
============

*Neisseria meningitidis*, the meningococcus, is a Gram‐negative bacterium belonging to the β‐proteobacteria. The species\' natural habitat is the human nasopharynx. Animal or environmental habitats are unknown. Asymptomatic colonization of the retropharyngeal wall and the tonsils is observed at high frequency in the second decade of life with a maximum in young adulthood ([@b26]; [@b22]). Carriage frequencies have been scarcely studied in elder individuals. In one Norwegian study, carriage rates of male, but not of female subjects in the third and fourth decade of life were comparable to the high rates in adolescents ([@b61]). Transmission is dependent on close contact between individuals or exposure to droplet aerosols.

*Neisseria meningitidis* is closely related to the pathogenic species *N. gonorrhoeae*, a sexually transmitted organism, and to the commensal *N. lactamica*, which colonizes the same niche as meningococci and exchanges DNA therewith ([@b66]). *Neisseria lactamica* may provide protection against invasive meningococcal disease (IMD) ([@b29]).

Genome sequences have been published for several strains of *N. meningitidis*([@b82]; [@b102]; [@b7]; [@b83]; [@b93]). In total, the NCBI genome resource lists 38 neisserial genome projects, which are either in progress or already completed. Genome sequences provide an invaluable repository for phylogenetic analyses, studies on the evolution of virulence, and of course for mining for vaccine targets.

The major pathogenicity factor of meningococci is the polysaccharide capsule. The ecological role of capsule expression is unclear, as unencapsulated strains thrive well in the nasopharynx. Furthermore, IMD is an accident during the bacterium\'s life cycle and may be considered as an evolutionary dead‐end implying costs only acceptable to very fit lineages of the species ([@b17]). The capsule possibly provides protection against desiccation during aerosol transmission. Furthermore, one might suggest that it protects the bacteria during colonization of inflamed mucosal tissue. However, the identification of apathogenic capsule null locus (*cnl*) meningococci proofs that meningococci might well proliferate in the population without capsule expression ([@b25]).

There are 12 biochemically distinct capsular polysaccharides. Serogroups B, C, W‐135 and Y, which are frequently observed in IMD, contain N‐acetyl‐neuraminic acid (Neu5Ac, sialic acid) ([@b9; @b10]). Serogroup A, a major cause of epidemics in Africa, expresses a capsule of (→6)‐α−[d]{.smallcaps}‐Man*p*NAc‐(1→OPO~3~→) ([@b18]). The α(2--8) linked sialic acid homopolymer of serogroup B is identical to a modification of the mammalian neural cell adhesion molecule (NCAM) ([@b104]), which explains why the serogroup B polysaccharide is poorly immunogenic. The serogroup B polysaccharide is structurally related to the serogroup C polysaccharide, an α(2--9) linked sialic acid homopolymer ([@b9]). This polysaccharide and those found in serogroup A, W‐135 and Y meningococci are highly immunogenic. W‐135 and Y meningococci express heteropolymeric polysaccharides composed of disaccharide units of sialic acid with either galactose or glucose respectively. The capsule polymerases of serogroups W‐135 and Y are more than 99% identical ([@b28]) with a single amino acid determining substrate specificity ([@b27]). Serogroup A, C, W‐135 and Y polysaccharides can be modified by O‐acetylation ([@b57]; [@b75]; [@b24]; [@b50]). O‐acetylated polysaccharide formulations of serogroup C were shown to elicit slightly lower antibody responses than de‐O‐acetylated ones, but this may also be an effect of the carrier protein of the polysaccharide, the conjugation chemistry and the length of the oligosaccharide ([@b88]). O‐acetylation is mandatory for immunogenicity of serogroup A polysaccharide ([@b8]). Serogroup X meningococci have recently emerged in Africa ([@b34]), but do not yet play a global role.

Serogroup distribution varies on a global scale ([@b100]), which makes it necessary to adapt vaccine strategies to regional needs. Whereas in Europe serogroups B and C dominate, serogroup Y plays an additional role in Northern America. Devastating epidemics due to serogroup A meningococci are observed in the African Meningitis Belt. [Figure 1](#f1){ref-type="fig"} demonstrates the serogroup distribution in Germany as an example. Of note, in contrast to several other European countries, meningococcus C (MenC) conjugate vaccination has been implemented in Germany quite late in 2006 and without a catch‐up campaign including adolescents. Therefore, serogroup C still plays a significant role.
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Incidences of meningococcal disease, i.e. sepsis and meningitis, in Europe and Northern America are low with values undulating around 1 per 100 000 inhabitants per year. Peak incidences are seen in infants, toddlers and adolescents, explaining the need for childhood vaccination programs. [Figure 2](#f2){ref-type="fig"} exemplifies age‐specific incidences using Germany as an example. The figure highlights differences between serogroup B and C. The low incidences of meningococcal disease provide a challenge for vaccine evaluation, because vaccine efficacy cannot be established in clinical trials and surrogates of protection need to be relied on before licensure.
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Meningococci exchange DNA by genetic transformation and homologous recombination. Recombination and selection shape clonal complexes, which are groups of related genotypes ([@b1]). Successful clonal complexes have been shown to be distributed internationally and to persist for decades ([@b21]). Members of a clonal complex tend to share alleles of immunogenic outer membrane proteins ([@b108]). Nevertheless, immune selection drives forward an extensive microevolution of surface antigens ([@b103]; [@b91]; [@b15]), which must be considered a major obstacle for the development of protein based vaccines, as vaccines need to cover a major share of variants and immune‐escape needs to be monitored.

Surveillance of meningococcal disease in many countries relies on statutory notification and a complementary active or passive laboratory surveillance program. Representative strain collections assembled by reference laboratories are a major resource for evaluation of protein based vaccines, because they can be used to study antigenic variability as well as susceptibility of strains towards bactericidal antibodies elicited by vaccines.

General problems faced in vaccine development
=============================================

A universal meningococcal vaccine is lacking ([Table 1](#t1){ref-type="table"}). Due to molecular mimicry, serogroup B capsular polysaccharide is poorly immunogenic, and manufacturers have been deterred from polysaccharide vaccine development by theoretical considerations of autoimmunity and potential fetal damage. A recent population based study from Denmark, however, failed to exhibit evidence for autoimmunity elicited by natural meningococcus serogroup B (MenB) infection ([@b55]).

###### 

Summary of vaccine concepts discussed.

  Vaccine composition                                                                                            Indication                                                       Status                                                                 Advantage                                                                                                                               Disadvantage
  -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  *Polysaccharide vaccines*                                                                                                                                                                                                                                                                                                                                                                      
   Plain polysaccharide                                                                                          Epidemic control                                                 On the market                                                          Low cost                                                                                                                                Uneffective in small children
  Travel medicine                                                                                                Efficacy                                                         For some serogroups booster doses are ineffective. No herd immunity.                                                                                                                                           
  Lab workers                                                                                                                                                                                                                                                                                                                                                                                    
   Protein conjugated polysaccharide                                                                             Routine toddler/infant/adolescent vaccination                    MenC: on the market                                                    Elicit herd immunity (proven for MenC)                                                                                                  Cost (for most preparations with the exception of the meningococcal A conjugate (PsA‐TT) vaccine).
  Epidemic control                                                                                               MenACWY: on the market/close to be marketed/in clinical trials   Efficacy in infants and toddlers                                       Waning immunity in young vaccinees                                                                                                      
  Travel medicine                                                                                                MenA: in clinical trials                                         Memory response                                                                                                                                                                                                
  Lab workers                                                                                                                                                                                                                                                                                                                                                                                    
  *OMV approaches*                                                                                                                                                                                                                                                                                                                                                                               
   Tailor made (OMVs of epidemic clones)                                                                         Epidemic control                                                 Programs have been introduced on several occasions                     Effective control of MenB outbreaks and epidemics                                                                                       Several doses required
  Immunogenicity in small children may be unsatisfying.                                                                                                                                                                                                                                                                                                                                          
  Lack of cross‐reactivity                                                                                                                                                                                                                                                                                                                                                                       
  Time consuming pre‐clinical and clinical trials.                                                                                                                                                                                                                                                                                                                                               
  Poor antibody persistence.                                                                                                                                                                                                                                                                                                                                                                     
   Multivalent PorA vaccines                                                                                     Broad protection against meningococci                            In clinical trials                                                     Theoretically covers most strains                                                                                                       Some PorA variants are poorly immunogenic
   OMV from GMO expressing one or more recombinant minor antigens, in some cases in a PorA negative background   Broad protection against meningococci                            Pre‐clinical                                                           May confer protection against a large panel of strains May avoid dominant effect of PorA                                                Pre‐clinical and clinical assessment of protection may be a difficult issue with regard to *in vivo* expression of antigens
   OMV from *N. lactamica*                                                                                       Broad protection against meningococci                            In clinical trials                                                     May confer protection against diverse meningococcal lineages, however, probably by mechanisms independent of bactericidal antibodies.   *N. lactamica* carriage in early childhood, which is likely to confer protection against meningococci, might be affected.
  Avoids dominant effect of PorA.                                                                                                                                                                                                                                                                                                                                                                
  *Subunit vaccines*                                                                                                                                                                                                                                                                                                                                                                             
   Genome derived recombinant multicomponent vaccine                                                             Broad protection against MenB                                    In clinical trials                                                     Combination of several targets ensures targeting of many lineages                                                                       Complex design
  Self‐adjuvating effects of OMVs                                                                                                                                                                                                                                                                                                                                                                
   Factor H binding protein presented in two allelic variants as lipoprotein                                     Broad protection against MenB                                    In clinical trials                                                     Two antigenic variants for broad coverage                                                                                               Depends on expression of factor H binding protein and the presence of cross‐reactive alleles
  Application of lipoprotein with self adjuvating effect                                                                                                                                                                                                                                                                                                                                         
   Meningococcal secretome                                                                                       Broad protection against meningococci                            Animal models                                                          Many components may ensure broad coverage                                                                                               Secretome yet not completely deciphered
  *MenB capsule derived approaches*                                                                                                                                                                                                                                                                                                                                                              
   N‐propionylated polysaccharide                                                                                Broad protection against MenB                                    In clinical trials                                                     Independent of antigenic variability                                                                                                    Theoretically possible induction of autoantibodies
  Poor induction of bactericidal antibodies in human volunteers                                                                                                                                                                                                                                                                                                                                  
   de‐N‐acetylated polysaccharide                                                                                Broad protection against MenB                                    Animal models                                                          Independent of antigenic variability                                                                                                    Theoretically possible induction of autoantibodies?
  Induction of memory response                                                                                                                                                                                                                                                                                                                                                                   
   Mimotope                                                                                                      Broad protection against MenB                                    Animal models                                                          Independent of antigenic variability                                                                                                    Theoretically possible induction of autoantibodies?
  Polysaccharide purification no longer needed                                                                                                                                                                                                                                                                                                                                                   
  *Live vaccine carriers*                                                                                                                                                                                                                                                                                                                                                                        
   *S. gordonae* expressing NadA and NhhA/Hsf                                                                    Broad protection against meningococci                            Animal models                                                          Use of attenuated or commensal organisms                                                                                                Regulatory issues: Release of GMOs
  Induction of colonization                                                                                      NadA not present in every meningococcal lineage                                                                                                                                                                                                                                 
  Induction of IgA response towards NadA                                                                                                                                                                                                                                                                                                                                                         
  Natural immunization route                                                                                                                                                                                                                                                                                                                                                                     
  Attenuated unencapsulated*N. meningitidis* strains (ΔsiaDΔrfaF or ΔsiaDΔmetH)                                  Broad protection against meningococci                            Animal models                                                          Protection of mice against heterologous strains                                                                                         Regulatory issues: release of GMOs
  Natural immunization route                                                                                                                                                                                                                                                                                                                                                                     

OMV, outer membrane vesicle; GMO, genetically modified organism.

Vaccine development against MenB is hampered by variability of surface antigens. Between 2002 and 2005 in Germany alone 33 and 69 variants of the PorA variable regions (VR) 1 and VR2, respectively, were observed ([@b36]). The meningococcal population is versatile and dynamic. There are emerging clones and lineages, and even neglected serogroups such as X may rise as a new problem as observed in Africa ([@b12]).

Specific aspects need to be addressed during meningococcal vaccine development. Licensure of modern meningococcal vaccines is mostly based on safety data, serological correlates of protection, and -- for MenB vaccines -- strain coverage. Efficacy studies are mostly conducted after vaccine introduction due to the low incidence of disease. Strain coverage is assessed by the analysis of protein expression in a representative strain panel and by determination of the allelic diversity ([@b5]; [@b68]; [@b77]). Serum bactericidal assays are a major effort for MenB vaccines, as in contrast to polysaccharide vaccines, several strains have to be tested. If proteins are used, which are not expressed under routine culture conditions, assay formats have to be adapted, which complicates assay standardization.

Furthermore, one has to consider that asymptomatic carriage is a double edged sword in light of vaccine development. The meningococcal serogroup C conjugate (MCC) vaccine campaign in the UK resulted in a reduction of carriage of a limited subset of strains ([@b70]), which probably will not affect natural boosting massively. Broadly active meningococcal vaccines, however, might also reduce carriage of apathogenic meningococci, such as *cnl* meningococci ([@b25]), and of *N. lactamica* due to cross reactive antigens ([@b46]; [@b47]). Since it is likely that apathogenic strains contribute to natural immunity against disease, an ideal vaccine would rather not touch these variants or species. On the other hand, the vaccine should strongly impact carriage of pathogenic variants to provide for herd immunity as evidenced for polysaccharide conjugate vaccines ([@b107]).

Meningococcal polysaccharide conjugate vaccine development
==========================================================

Several MCC vaccines have been licensed, which differ with regard to O‐acetylation of the polysaccharide, protein conjugate, conjugation chemistry and adjuvant. The vaccines are considered as safe ([@b86]). The UK in 1999 introduced MCC vaccines, which was highly successful and as an added value provided striking scientific knowledge. The efficacy of the vaccines was about 90%. However, there was an age‐dependent decline of efficacy over time following vaccination ([@b97; @b98]; [@b14]). This finding led to the recommendation of a booster vaccination in the infant immunization schedule ([@b105]). Maintenance of protective titres seems to be essential as the time required for an effective booster response elicited by acquisition of a MenC strain probably exceeds the incubation period ([@b3]). The success of the vaccination campaign was in large parts due to the fact that herd immunity was elicited ([@b87]; [@b106]). Herd immunity depended on mucosal immunity towards MenC carriage in the UK, which was considerably reduced ([@b72]; [@b70]). Vaccination of adolescents is most effective in this regard, as carriage rates of meningococci increase in the second decade of life ([@b26]). One might have speculated that rates of serogroup switching (genetic alteration of a clone) or replacement (increased occurrence of a variant not expressing the vaccine antigen), which have been shown for meningococci on several occasions ([@b112]), will increase under selective pressure induced by vaccination campaigns ([@b71]). However, the UK disease surveillance did not evidence for increased serogroup switching and replacement ([@b4]; [@b70]). The occurrence of serogroup switch variants was reported for Spain ([@b19]). It is unclear whether this observation was due to a different vaccine introduction strategy.

The success of MCC stimulated the introduction and development of novel MenACWY conjugate vaccines ([@b60]; [@b99]; [@b80]) and also of combinations of conjugated meningococcal polysaccharide with other components, such as the *H. influenzae* type b polysaccharide ([@b13]). The serological data published until now for tetravalent polysaccharide vaccines are promising; instruments to control MenACWY disease seem to be available now. However, data are needed on the induction of herd immunity. Of interest is further the development of a serogroup A conjugate vaccine by the Meningitis Vaccine Project (MVP) and collaborating agencies ([@b62]; [@b63]), which hopefully will provide a solution to the devastating serogroup A epidemics in the African meningitis belt.

Subcapsular vaccine targets
===========================

There is a variety of highly immunogenic structures in the outer membrane, which serve as possible vaccine components. A catalogue has been published recently ([@b39]) that categorizes possible candidates as major outer membrane proteins, iron uptake proteins, adhesins, other virulence factors, antigens with unknown function or those involved in membrane architecture, and enzymes. Major outer membrane proteins such as porins are expressed at high amounts ([@b43]). Other proteins are repressed under *in vitro* culture conditions, but can be observed, e.g. after iron depletion ([@b49]). Outer membrane proteins frequently are hard to express or purify in native conformation, so that alternative strategies have to be employed such as the production of outer membrane vesicles (OMVs) ([@b11]; [@b95]; [@b32]). A variety of lipidated proteins have been described as possible meningococcal vaccine antigens ([@b42]; [@b33]; [@b56]), which are attractive due to their self‐adjuvanting activity.

Besides the induction of bactericidal antibodies, which activate serum complement resulting in bacterial cell death, antibodies against some targets block their function. Some monoclonal antibodies against the meningococcal factor H binding protein (FHBP) bind in close proximity to the factor H binding site and block factor H binding ([@b6]). Although the structure of FHBP has been resolved ([@b20]; [@b73]; [@b92]), precise binding sites of antibodies elicited in vaccinees have not been reported to our knowledge.

Proteins involved in iron uptake have been investigated intensively for their vaccine potential. The transferrin binding protein TbpA and even more so the TbpB are immunogenic and protect mice from meningococcal challenge, e.g. when delivered as recombinant antigen ([@b114]). Antigenic variability has to be considered for Tbps, and it has been shown for TbpB that there are two families or isotypes with isotype I being shared between sequence type 11 meningococci and apathogenic species ([@b51]).

Proteins abundantly present on the meningococcal cell are easily accessible by bactericidal antibodies. However, harsh immune selection may trigger immune escape variants, generated by meningococci through horizontal gene transfer ([@b38]). It has been suggested that overexpression of poorly expressed minor proteins in a PorA negative genetic background has a synergistic effect by augmenting the topical concentration of bactericidal antibodies on the bacteria above threshold values critical for complement activation ([@b116]).

Besides protein antigens, lipopolysaccharide (LPS) has been considered a possible immunogen active against MenB ([@b115]). LPS has self‐adjuvant activity, but is toxic. Assays have been developed to study the biological effects of LPS in OMVs ([@b101]). Detoxification of LPS in OMV preparations is delicate, as detergent extraction also reduces the amount of immunogenic lipoproteins. LpxL1 mutants impaired in lipid A acylation were shown to retain adjuvant effects while being less toxic ([@b110]). Lipid A acylation mutants therefore provide a solution to the toxicity of OMVs.

To combat a regional epidemic, tailor‐made meningococcal vaccines have been developed, which are OMVs derived from the epidemic strain ([@b53]). The immunodominant antigen of OMVs is the porin A (PorA). Tailor‐made vaccines have been used in Norway, Chile, Cuba and New Zealand ([@b11]; [@b95]; [@b32]; [@b79]). These vaccines in general have to be delivered in three to four doses. The antibody response increases with age, as does the cross‐reactivity towards strains with differing antigens. It is debatable whether strain‐specific OMV vaccines have the practical potential to be developed in a flexible fashion in analogy to annual influenza vaccine preparations. Nevertheless, they have proven to be effective in New Zealand ([@b59]) recently and have been introduced in the Normandie to combat an outbreak of MenB disease ([@b90]).

Up to nine different PorA variants are included in OMV preparations by recombinant technology in order to increase the theoretical strain coverage ([@b109]). Outer membrane vesicles have also been used as vehicles to present other recombinant antigens in native conformation ([@b54]; [@b116]). Finally, OMVs are added to the present formulation of the Novartis investigational vaccine ([@b89]).

Outer membrane vesicles of *N. lactamica*, which lacks the immuno‐dominant PorA protein, are in development ([@b78]; [@b47]). Interestingly, these vaccines seem to only poorly elicit bactericidal antibodies, but protect mice from bacterial challenge, probably by augmenting opsonophagocytosis ([@b41]). In a phase I clinical trial the vaccine as well displayed a stronger effect on opsonophagocytosis than on bactericidal antibody concentrations, which was rather low ([@b47]).

Subunit vaccines containing recombinant meningococcal proteins now play a prominent role in the field of investigational vaccines for meningococci. The groundbreaking approach of 'reverse vaccinology' demonstrates how genome research results in potential products ([@b89]), and along the way enhances the understanding of meningococcal pathogenicity ([@b85]; [@b30]; [@b35]). Predicted surface exposed proteins were tested for immunogenicity. Consecutively, it was investigated whether the proteins elicited bactericidal antibodies. Finally, a broadly reactive subunit vaccine was designed of recombinant proteins partly presented as fusion proteins ([@b45]). One of the proteins is FHBP, previously referred to as GNA1870 ([@b69]), a regulator of the complement cascade. Recruitment of factor H on the bacterial surface blocks consecutive complement activation. Wyeth, also identified FHBP as a vaccine target using biochemical approaches ([@b42]; [@b84]; [@b74]). The protein was designated LP2086 and is included in two antigenic lipoprotein variants in the investigational vaccine.

Alternative concepts
====================

The MenB polysaccharide, a poor antigen eliciting low affinity antibodies, has been modified by N‐propionylation to reduce cross‐reactivity towards human glycosylated proteins and augment immunogenicity ([@b58]; [@b2]; [@b44]). Unfortunately, N‐propionylated polysaccharides elicited antibodies cross‐reactive with human α‐2,8‐linked polysialic acid, the glycosylation of the neural cell adhesion molecule NCAM ([@b48]). Furthermore, a human trial with an N‐propionylated MenB capsular polysaccharide conjugated to tetanus toxoid was dissatisfying, because the vaccine did not elicit functional antibodies ([@b16]). Another MenB polysaccharide modification currently tested in animal models is de‐N‐acetyl MenB polysaccharide ([@b76]). Removing N‐acetyl groups at the non‐reducing end of the polysaccharide obviously stimulates T cell help and supports the induction of IgG in mice. The search for MenB polysaccharide modifications further stimulated the investigation of polysaccharide mimotopes, e.g. by screening phage display libraries with group B specific monoclonal antibodies lacking affinity to human polysialic acid ([@b94]; [@b81]). Vaccination of mice with mimotopes resulted in bactericidal antibodies ([@b67]).

Another concept pursued is the vaccination of animals with secreted proteins of meningococci obtained from cell‐ and vesicle‐free supernatants ([@b65]). The secretome of meningococci has been reviewed recently ([@b111]). [@b65]) suggest that secreted proteins partly stick to the outer membrane, thereby serving as targets for bactericidal antibodies.

Of interest is the investigation in animal models of attenuated meningococcal strains as live vaccines such as unencapsulated strains with the genotype Δ*siaD*Δ*rfaF* or Δ*siaD*Δ*metH*([@b64]). Furthermore, [@b23]) reported *Streptococcus gordonii* strains expressing the adhesin NadA ([@b30]) and the putative serum resistance modulator NhhA ([@b96]), which induced the mucosal secretion of specific IgA in mice ([@b23]). NadA is probably not the best choice for broad protection against meningococci, as it is not expressed in a variety of IMD‐associated strains ([@b31]; [@b37]; [@b68]). Nevertheless, vaccination with live bacteria is an interesting issue to pursue. We suggest to consider also *cnl* meningococci, which are constitutively unencapsulated and widely present among healthy carriers ([@b25; @b26]). IMD caused by *cnl* meningococci is extremely rare. We reported one case in a severely immunocompromised patient ([@b113]), who was the only *cnl* IMD case among more than 3400 cases investigated by the reference laboratory between 2002 and 2009. There are two further case reports of invasive disease due to *cnl* meningococci with one fatal case from Canada and three cases from Burkina Faso ([@b52]; [@b40]). There is evidence that *cnl* meningococci represent ancestors of meningococci ([@b93]). Uptake of the capsule locus is possible in the laboratory (own unpublished observation), but unlikely to occur in nature based on genetic analysis of carrier isolates and theoretical consideration taking into account the size of the DNA fragment harbouring the capsule locus. Data are needed for the persistence of carriage of capsule null locus meningococci and the induction of bactericidal antibodies during carriage. Furthermore, the effect of live immunization practices on the population structure of the bacteria and natural boosting would need to be addressed.

Conclusions
===========

The next years will see the introduction of conjugated meningococcus A vaccines in Africa, of new conjugated tetravalent vaccines, and hopefully also of the first broadly cross‐reactive MenB vaccines. A variety of MenB protein vaccine candidates with possibly broad cross‐reactivity also among other serogrups are under investigation, with the ones using the FHBP being advanced farthest. It is difficult to provide an estimate of the potential coverage of FHBP vaccines due to geographic effects, the unknown impact of carriage, and the unknown velocity and effectiveness of immune escape once effective herd immunity has been established. Many questions will only be answered after licensure, and one may assume that the first generation of universal MenB protein vaccines will be a starting point of continuous development. For sure, MenB vaccines might affect the population structure of the bacteria and consequently the development of natural immunity. Therefore, carriage studies are necessary, as well as an effective post‐licensure surveillance of disease. The integration of various players during MenB vaccine development and introduction is summarized in [Fig. 3](#f3){ref-type="fig"}.
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